secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0000950170-24-029239
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma Q4 2023: R&D expenses up to $24.5M; cash $235M; pipeline progress on ORIC-944/114
--------------------------------------------------------------------------------

- Q4 2023 R&D expenses $24.5M (up $8.2M YoY); G&A $6.9M; cash and investments $235M at Dec 31, 2023.
- Two private placements raised $85M (June 2023) and $125M (Jan 2024); pro forma cash $351.8M at Jan 31, 2024, funding into late 2026.
- Initial Phase 1b data for ORIC-114 (EGFR/HER2) and ORIC-944 (PRC2) show best-in-class potential; dose expansion for ORIC-114 in mutated NSCLC expected H1 2024.
- ORIC-533 (CD73 inhibitor) Phase 1b dose escalation completed Q1 2024; company plans strategic partnership for combination studies.
- ORIC-944 combination study with AR inhibitor to start H1 2024; program update mid-2024. Discovery includes PLK4 inhibitor ORIC-613 advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/0000950170-24-029239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/oric-20240311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer